1alpha,25-Dihydroxyvitamin D3 Protects Dopaminergic Neurons in Rodent Models of Parkinson's Disease through Inhibition of Microglial Activation
Journal of Clinical Neurology
;
: 252-257, 2006.
Article
in English
| WPRIM
| ID: wpr-224885
ABSTRACT
BACKGROUND:
Recent studies have demonstrated the molecular basis of the immunomodulatory and anti-inflammatory activities of 1,25-dihydroxyvitamin D3(1,25-(OH)2D3). This hormone improves behavioral deficits and normalizes the nigral dopamine levels in animal models of Parkinson's disease (PD).METHODS:
We studied whether the administration of 1,25-(OH)2D3 would protect against 6-hydroxydopa (6-OHDA)- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neuronal injury, and its potential regulatory effect on microglia activation.RESULTS:
We found that 1,25-(OH)2D3 pretreatment significantly decreased 6-OHDA- and MPTP-induced dopaminergic neuronal loss in the substantia nigra pars compacta by preventing the activation of microglia. This observed neuroprotective effect in MPTP-treated mice that were given 1,25-(OH)2D3 may be attributable to inhibition of proinflammatory cytokine expression.CONCLUSION:
These results suggest that 1,25-(OH)2D3 is a potentially valuable neuroprotective agent; it may therefore be considered for the treatment of pathologic conditions of the central nervous system, such as PD, where inflammation-induced neurodegeneration occurs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Parkinson Disease
/
Rodentia
/
Vitamin D
/
Substantia Nigra
/
Dopamine
/
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
/
Central Nervous System
/
Microglia
/
Neuroprotective Agents
/
Models, Animal
Limits:
Animals
Language:
English
Journal:
Journal of Clinical Neurology
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS